Helix Biopharma Corp.
HBP.TO
TSX
| 07/31/2025 | 04/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -24.06% | 45.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.19% | 20.18% | |||
| Operating Income | 36.19% | -20.18% | |||
| Income Before Tax | 36.34% | -12.27% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 36.34% | -12.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.34% | -12.27% | |||
| EBIT | 36.19% | -20.18% | |||
| EBITDA | 36.12% | -20.13% | |||
| EPS Basic | 52.20% | -6.22% | |||
| Normalized Basic EPS | 52.34% | -4.92% | |||
| EPS Diluted | 52.20% | 49.26% | |||
| Normalized Diluted EPS | 52.34% | -4.92% | |||
| Average Basic Shares Outstanding | 33.67% | 5.93% | |||
| Average Diluted Shares Outstanding | 33.67% | 5.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||